Brief: G1 Therapeutics Announces Investigator Initiated Study Of Trilaciclib And Lurbinectedin
26/10/2022 14:34
Oct 26 (Reuters) - G1 Therapeutics Inc GTHX.O :
* G1 THERAPEUTICS ANNOUNCES INVESTIGATOR INITIATED STUDY OF
TRILACICLIB AND LURBINECTEDIN IN PATIENTS WITH EXTENSIVE STAGE
SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX7gBS43
Further company coverage: GTHX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on G1 Therapeutics
See all newsG1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney
U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify